Onset and spread of dyskinesias and motor symptoms in Parkinson's disease

Movement Disorders

Volumn 24, Issue 14, 2009, Pages 2091-2096

  Fabbrini, Giovanni ^a   Defazio, Giovanni ^b   Colosimo, Carlo ^a   Suppa, Antonio ^a   Bloise, Maria ^a   Berardelli, Alfredo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Basal ganglia; Dyskinesias; L dopa; Parkinson disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AGED; ARM; ARTICLE; ATLANTOOCCIPITAL JOINT; BASAL GANGLION; CHRONIC DRUG ADMINISTRATION; CLINICAL EXAMINATION; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DYSKINESIA; FEMALE; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; MOTOR CORTEX; MOTOR DYSFUNCTION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DYSKINESIA, DRUG-INDUCED; FEMALE; FUNCTIONAL LATERALITY; HAND STRENGTH; HUMANS; ITALY; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS; MOVEMENT; MOVEMENT DISORDERS; PARKINSON DISEASE; RETROSPECTIVE STUDIES;

EID: 70450186850     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22703     Document Type: Article

References (38)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations and disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders, Vol 2. London: Butterworth; 1982. p 96-105.
2. Fahn S. The spectrum of Levodopa-induced dyskinesias. Ann Neurol 2000;47 (Suppl 1):S2-S11.
3. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20 (Suppl 11):S11-S16. (Pubitemid 40846906)
4. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389.
5. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:668-673.
6. Horstink MWIM, Zjilmans JCM, Pasman JW, Berger HJC, van't Hof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53:224-226.
7. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994;9:2-12. (Pubitemid 24022609)
8. Vidailhet M, Bonnet AM, Marconi R. The phenomenology of Ldopa- induced dyskinesias in Parkinson's disease. Mov Disord 1999;14 (Suppl 1):13-18. (Pubitemid 29509469)
9. Vidailhet M, Bonnet AM, Marconi R, Gouidier-Khouja N, Agid Y. Do parkinsonian symptoms and L-Dopa induce dyskinesias start in the foot? Neurology 1994;44:1613-1616.
10. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopainduced dyskinesias in Parkinson's disease. J Neurol 1999;246:1127-1133. (Pubitemid 30021235)
11. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988;23:73-78 (Pubitemid 18219218)
12. Kidron D, Melamed E. Forms of dystonia in Parkinson's disease. Neurology 1987;37:1009-1011.
13. Barbeau A. L-Dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 1969;101:59-68.
14. Boshes B. Sinemet and the treatment of parkinsonism. Ann Intern Med 1981;94:364-370.
15. Godwin-Austen RB, Tomlinson EB, Frears CC, Kok HWL. Effects of L-Dopa in Parkinson's disease. Lancet 1969;2:165-168.
16. Lee JE, Sweet RD, McDowell FH. Treatment of Parkinsonism with Levodopa: follow-up after 2 years of treatment. Ann Intern Med 1971;75:703-708.
17. Klawans HL, Goetz C, Nausieda PA, Weiner WJ. Levodopa induced dopamine receptor hypersensitivity. Trans Am Neurol Assoc 1977;102:80-83.
18. DeLong M, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007;64:20-24. (Pubitemid 46072419)
19. Obeso J, Rodriguez-Oroz MC, Benitez-Temino M, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 2008;23 (Suppl 3):S48-S59.
20. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
22. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent development in Parkinson's disease, Vol2. Florham Park, NJ: MacMillan Healthcare information; 1987. p 153-163.
23. Guy W. Abnormal involuntary movement scale. ECDEU assessment manual for psychopharmacology. Washington, DC: US Government Printing Office; 1976. p 534-537.
24. Mouradian MM, Juncos J, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms: Part II. Ann Neurol 1988;24:372-378. (Pubitemid 18233136)
25. Cenci MA, Lundblad M. Post-versus pre-synaptic plasticity in LDOPA- induced dyskinesia. J Neurochem 2006;99:381-392.
26. Quik M, Cox H, Parameswaran N, O'Leary K, Langston WJ, Di Monte D. Nicotine reduces Levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62:588-596.
27. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesias. Mov Disord 2005;20:919-931.
28. Muñoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008;131:3380-3394.
29. Vitek JL, Bakay RA, Hashimoto T, et al. Microelectrode-guided pallidotomy: technical approach and its application in medically intractable Parkinson's disease. J Neurosurg 1998;88:1027-1043. (Pubitemid 28261850)
30. Kishore A, Panikar D, Balakrishnan S, Joseph S, Sarma S. Evidence of functional somatotopy in GPi from results of pallidotomy. Brain 2000;12:2491-2500.
31. Rodriguez-Oroz MC, Rodriguez M, Guridi J, et al. The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain 2001;124:1777-1790. (Pubitemid 32845439)
32. Abosch A, Hutchison WD, Saint-Cyr JA, Dostrovsky JO, Lozano AM. Movement-related neurons of the subthalamic nucleus in patients with Parkinson disease. J Neurosurg 2002;97:1167-1172. (Pubitemid 35253554)
33. Theodosopoulos PV, Marks WJ, Christine C, Starr PA. Locations of movement-related cells in the human subthalamic nucleus in Parkinson's disease. Mov Disord 2003;18:791-798. (Pubitemid 36939974)
34. Romanelli P, Esposito V, Schaalb DW, Heit G. Somatotopy in the basal ganglia: experimental and clinical evidence for segregated sensorimotor channels. Brain Res Rev 2005;48:112-128. (Pubitemid 40215785)
35. Filion M, Tremblay L, Bedard PJ. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res 1988;44:165-176. (Pubitemid 18071205)
36. Boraud T, Bezard E, Bioulac B, Gross CE. Ratio of inhibited-to activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. J Neurophysiol 2000;83:1760-1763. (Pubitemid 30159597)
37. Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchison WD, Lozano AM. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 2001;86:249-260. (Pubitemid 32623230)
38. Fahn S, Jankovic J. Principles and practices of movement disorders. Philapdelphia, PA: Churchill Livingstone Elesvier; 2007. p 155.